The anti-proliferative effects of interferon gamma (IFN-γ) and CPT-11, a new derivative of camptothecin, both singly and in combination, on two human endometrial carcinoma cell lines, HHUA and ISHIKAWA, were examined in vitro. The HHUA cells were responsive dose-dependently to IFN-γ, while the ISHIKAWA cells were unresponsive to IFN-γ. Both cell lines were responsive dose-dependently to CPT-11. In both cell lines, IFN-γ at clinically achievable concentrations (10 and 100 U ml−1 enhanced the anti-proliferative activity of CPT-11 in the range of concentrations where CPT-11 showed more than 10% cell growth inhibition. Sequential treatment with CPT-11 followed by incubation with IFN-γ resulted in significant cell growth inhibition, but not vice versa. Flow cytometric studies indicated that the combined anti-proliferative effect did not correlate with cytokinetic alterations. Treatment with IFN-γ did not change the extractable topoisomerase I activity of the HHUA and ISHIKAWA cells. The combination therapy of IFN-γ and CPT-11 could provide a new approach against endometrial cancer.
- anti-proliferative activity
- camptothecin analog
- cell cycle
- endometrial carcinoma cell line
- interferon gamma (IFN-γ;)
- topoisomerase I activity
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.